Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2009 Mar;18(3):349-58. doi: 10.1517/13543780902780175 .

Review of rifaximin as treatment for SIBO and IBS.

Author information

1
GI Motility Program, Cedars-Sinai Medical Center, 8730 Alden Dr, Suite 225E, Los Angeles, CA 90048, USA. Mark.Pimentel@cshs.org

Abstract

BACKGROUND:

Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).

OBJECTIVE:

To review rifaximin for treatment of IBS and SIBO.

METHODS:

Review of rifaximin clinical trials.

RESULTS/CONCLUSION:

Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.

PMID:
19243285
DOI:
10.1517/13543780902780175
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center